OCS OCULIS HOLDING AG

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended.

Attachments



EN
20/03/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes 2025 Consolidated Financial Statements

Oculis Publishes 2025 Consolidated Financial Statements ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now been filed with the SEC on form 20-F, are attached. Attachments

March 5, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Participate in Upcoming Investor Conferences

Oculis to Participate in Upcoming Investor Conferences ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor conferences in March. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader i...

March 5, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Participate in Upcoming Investor Conferences

Oculis to Participate in Upcoming Investor Conferences ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor conferences in March. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader i...

March 5, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment

March 4, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2025 og kynnir ...

Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2025 og kynnir áfanga í rekstri félagsins ZUG, Sviss, March 03, 2026 (GLOBE NEWSWIRE) -- Árið 2025 náðist mikilvægur árangur, sem gerir Oculis kleift að ná ýmsum klínískum áföngum í rannsóknum á síðari stigum. Þar er fyrst um að ræða væntanlegar fyrstu niðurstöður (e. topline results) úr DIAMOND fasa 3 rannsóknum á OCS-01 augndropum við sjónhimnubjúg af völdum sykursýki (e. diabetic macular edema, DME) á öðrum ársfjórðungi 2026 Privosegtor hlaut stöðu byltingarkennds meðferðarlyfs sem styrkir PIONEER skráningarrannsóknaráætlunina á sj...

March 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch